Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034541 · ClinicalTrials.gov registry record · Phase 1
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00034541 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 32 participants.
The verdict
NCT00034541, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- BIOLOGICAL cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2000-12 |
| Est. Completion | 2003-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034541
The ClinicalTrials.gov registry entry for NCT00034541 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00034541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00034541 about?
NCT00034541 is a clinical study titled "Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer". The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patie...
What is the current status of trial NCT00034541?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2000-12. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00034541?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00034541?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.